NPS Pharmaceuticals Inc. (NASDAQ:NPSP) has been moving in a range since the open Friday, but has spiked higher in the last few minutes on increased volume. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) net profit margin is -7.10% and weekly performance is 18.86%. On last trading day company shares ended up $31.13. Analysts mean target price for the company is $39.73. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) distance from 50-day simple moving average (SMA50) is 15.12%.
22nd Century Group, Inc. (NYSE MKT:XXII) announced that its subsidiary, Goodrich Tobacco Company LLC, signed a letter of intent with Orion, a cigarette manufacturer based in Poland, to contract manufacture the Company’s proprietary tobacco products to be distributed in the European Union. 22nd Century Group Inc. (NYSEMKT:XXII) shares advanced 8.16% in last trading session and ended the day on $3.05. XXII return on assets is -468.20%.22nd Century Group Inc. (NYSEMKT:XXII) quarterly performance is -29.72%.
Aastrom Biosciences Inc. (NASDAQ:ASTM) reported on 15 may, a net loss for the quarter ended March 31, 2014 of $6.0 million, or $1.26 per share, compared to $5.5 million, or $3.00 per share, for the same period a year ago. Aastrom Biosciences Inc. (NASDAQ:ASTM) shares moved up 7.68% in last trading session and was closed at $5.05, while trading in range of $4.56 – $5.19. Aastrom Biosciences Inc. (NASDAQ:ASTM) year to date (YTD) performance is 56.35%.
On May 15, 2014, Medgenics, Inc. (NYSEMKT:MDGN) a Delaware corporation and Dr. Eugene Bauer, a director of the Company, terminated the Consulting Services Agreement dated October 18, 2010, as amended on April 1, 2012 (the “Consulting Agreement”), pursuant to which Dr. Bauer provided financial, strategic, business development, investor relations and clinical and regulatory consulting services to the Company. Medgenics Inc. (NYSEMKT:MDGN) ended the last trading day at $7.80. Company weekly volatility is calculated as 6.15% and price to cash ratio as 7.66.Medgenics Inc. (NYSEMKT:MDGN) showed a positive weekly performance of 11.27%.
La Jolla Pharmaceutical Company (NASDAQ:LJPC) a leader in the development of therapeutics targeting significant unmet life-threatening diseases, announced that George Tidmarsh, MD, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Jefferies 2014 Global Healthcare Conference taking place June 2-5 in New York City.La Jolla Pharmaceutical Company (NASDAQ:LJPC) weekly performance is 5.46%. On last trading day company shares ended up $8.11. Analysts mean target price for the company is $34.75. La Jolla Pharmaceutical Company (NASDAQ:LJPC) distance from 50-day simple moving average (SMA50) is -18.02%.